ArticleHeliyon2024

Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns.

Paul-Rémi Petit et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.